Search Result

Results for "

αv integrin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Integrin (89) Akt (3) Apoptosis (4) Autophagy (1) Biochemical Assay Reagents (1) Complement System (1) Drug Intermediate (3) Elastase (1) Endogenous Metabolite (2) ERK (1) FAK (1) Fluorescent Dye (2) Interleukin Related (1) Liposome (4) MMP (1) PD-1/PD-L1 (2) PI3K (1) Radionuclide-Drug Conjugates (RDCs) (4) Reference Standards (4) TGF-beta/Smad (2) TGF-β Receptor (2)
By Research Areas:	Cancer (71) Cardiovascular Disease (8) Endocrinology (1) Infection (2) Inflammation/Immunology (20) Metabolic Disease (1) Neurological Disease (2)
Oligonucleotides:	Pegylated Lipids (4)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Antibodies

Oligonucleotides

Targets Recommended: Integrin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0023

Cyclo(-RGDfK) Maximum Cited Publications 27 Publications Verification	Integrin	Cancer
Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC₅₀ of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-100563A

Cyclo(RGDyK) 4 Publications Verification	Integrin	Cancer
Cyclo(RGDyK) is a potent and selective **α_Vβ₃ integrin inhibitor with an IC₅₀** of 20 nM.

HY-100506

GLPG0187 15+ Cited Publications	Integrin	Cancer
GLPG0187 is a broad spectrum *integrin* receptor antagonist with antitumor activity; inhibits α_vβ₁-integrin with an IC₅₀ of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .

HY-137561

Bexotegrast 3 Publications Verification PLN-74809	Integrin	Inflammation/Immunology
Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with K_d of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC₅₀ values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung .

HY-P0122

iRGD peptide 5+ Cited Publications c(CRGDKGPDC)	Integrin	Cancer
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to *αv-integrins*, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

HY-18644

CWHM-12 5+ Cited Publications	Integrin	Cancer
CWHM-12 is a potent inhibitor of αV integrins with IC₅₀s of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1.

HY-P0023A

Cyclo(-RGDfK) TFA Maximum Cited Publications 27 Publications Verification	Integrin	Cancer
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-P2300

Cyclo(Arg-Gly-Asp-D-Phe-Cys) 2 Publications Verification Cyclo(RGDfC)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .

HY-16143

Cilengitide TFA Maximum Cited Publications 70 Publications Verification EMD 121974 TFA	Integrin Autophagy	Cancer
Cilengitide is a potent and selective *integrin* inhibitor for α_vβ₃ and α_vβ₅ receptor, with IC₅₀ values of 4 nM and 79 nM, respectively.

HY-15102

MK-0429 5+ Cited Publications L-000845704	Integrin	Inflammation/Immunology Cancer
MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide *pan-integrin* antagonist with IC₅₀ values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively .

HY-W008859

Tetrac 1 Publications Verification Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid	Integrin Endogenous Metabolite	Cancer
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .

HY-W087027

Maleimide-NOTA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Integrin	Cancer
Maleimide-NOTA is a chelate. Maleimide-NOTA can be site-specifically coupled to the hPD-L1 nanobody bearing the Cys-tag. Maleimide-NOTA can specifically conjugate to A20FMDV2 (HY-P1654). The [ ⁶⁸Ga]Ac-CG6 formed by the conjugation of ⁶⁸Ga radiolabeled Maleimide-NOTA with A20FMDV2 can be used for PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma .

HY-172494

DSPE-PEG2000-iRGD	Liposome Integrin Drug Intermediate Complement System	Cancer
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an *αv-integrins* targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for agent delivery .

HY-149136

MORF-627	Integrin TGF-beta/Smad	Inflammation/Immunology
MORF-627 is a highly selective, orally active integrin αvβ6 inhibitor. By blocking TGF-β1 activation and pSMAD2 signaling, MORF-627 significantly reduces collagen deposition, epithelial-mesenchymal transition markers, and structural changes in fibrotic cells. MORF-627 exhibits significant antifibrotic efficacy without genotoxicity in idiopathic pulmonary fibrosis models. However, MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, and this toxic effect can be reversed by exogenous TGF-β. MORF-627 can be used for studying the pathological mechanisms of pulmonary fibrosis and evaluating drug safety .

HY-100445A

*αvβ1 integrin-IN-1 TFA* 5+ Cited Publications	Integrin	Cardiovascular Disease Cancer
αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC₅₀ of 0.63 nM. Antifibrotic effects .

HY-P5133

Synstatin (92-119) 1 Publications Verification SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an inhibitor of αvβ3/αvβ5 integrins and IGF1R with anti-angiogenic, anti-proliferative, antioxidant and anti-tumor activities. Synstatin (92-119) competitively blocks the capture of αvβ3/αvβ5 integrins and IGF1R by syndecan-1, disrupts the formation of the syndecan-1 : integrin : IGF1R ternary complex, inhibits integrin activation and talin-mediated signaling pathways, and blocks VEGF-induced angiogenesis. Synstatin (92-119) is applicable to research related to cancer and hepatocellular carcinoma .

HY-19767

GSK 3008348 2 Publications Verification	Integrin TGF-β Receptor	Infection Inflammation/Immunology Cancer
GSK 3008348 is a small molecule antagonist of integrin αvβ6 with IC₅₀ values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 can be used for research on pulmonary fibrosis and various types of cancer .

HY-100563

Cyclo(RGDyK) trifluoroacetate 4 Publications Verification	Integrin	Cancer
Cyclo(RGDyK) trifluoroacetate is a potent and selective **α_Vβ₃ integrin inhibitor with an IC₅₀** of 20 nM.

HY-19307

SB-273005	Integrin Interleukin Related	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
SB-273005 is an orally active non-peptide αvβ3 integrin antagonist with K_i values of 1.2 nM and 0.3 nM for αvβ3 and αvβ5, respectively. SB-273005 blocks the binding of integrins to the RGD sequence in the extracellular matrix. SB-273005 inhibits Rictor phosphorylation and reduces IL-10 secretion. SB-273005 inhibits inflammation, prevents bone loss, regulates vascular smooth muscle function, and reverses pregnancy-induced immune deviation. SB-273005 can be used in the study of rheumatoid arthritis, osteoporosis, and aneurysms. .

HY-P99296

Intetumumab CNTO 95; Anti-Human CD51 Recombinant Antibody	Integrin Apoptosis	Cancer
Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a K_d value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .

HY-145363

*αvβ5 integrin-IN-1* 1 Publications Verification	Integrin	Cancer
αvβ5 integrin-IN-1 (Compound 12) is a selective αvβ5 inhibitor (pIC₅₀ = 8.2). αvβ5 integrin-IN-1 exhibits 800-fold selectivity for αvβ5 versus αvβ3 .

HY-100445

*αvβ1 integrin-IN-1* 5+ Cited Publications	Integrin	Cardiovascular Disease Cancer
αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC₅₀ of 0.63 nM. Antifibrotic effects .

HY-P5098

E(c(RGDfK))2	Integrin	Neurological Disease Cancer
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .

HY-P3732

RGD-4C	Integrin	Cancer
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

HY-P99291

Etaracizumab LM609; MEDI-522	Integrin Apoptosis Akt	Cancer
Etaracizumab (LM 609) is an α_vβ₃ integrin IgG mAb. Etaracizumab is developed to target α_vβ₃+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofα_vβ₃-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-130119

Integrin-IN-2	Integrin	Cancer
Integrin-IN-2 (compound 39) is an orally bioavailable pan αv integrin inhibitor. Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC₅₀ values of 7.8, 8.4, 8.4 and 7.4, respectively .

HY-19767A

GSK 3008348 hydrochloride 2 Publications Verification	Integrin TGF-β Receptor	Infection Inflammation/Immunology Cancer
GSK 3008348 hydrochloride is a small molecule antagonist of integrin αvβ6 with IC₅₀ values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 hydrochloride can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 hydrochloride prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 hydrochloride can be used for research on pulmonary fibrosis and various types of cancer .

HY-P990667

STX-100 BG00011	Integrin TGF-beta/Smad	Inflammation/Immunology Cancer
STX-100 (BG00011) is a humanized monoclonal antibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer .

HY-164360

αVβ8-IN-1	Integrin	Inflammation/Immunology Cancer
αVβ8-IN-1 is a αVβ8 integrin inhibitor. αVβ8-IN-1 has been shown to inhibit the growth of tumors such as EMT6, CT26, KPC, and TKCC-10. αVβ8-IN-1 can be used in research related to idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and tumors .

HY-P0295

Gly-Arg-Gly-Asp-Ser GRGDS	Integrin	Others
Gly-Arg-Gly-Asp-Ser (GRGDS) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC₅₀ of ～5 and ～6.5 μM

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC₅₀ values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .

HY-100133A

DOTA-ADIBO TFA	Integrin	Cancer
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-B0665

Fibrin	Integrin	Cardiovascular Disease
Fibrin is an insoluble protein found in blood that is produced in response to bleeding. As the main component of blood clots, fibrin functions in blood coagulation. Fibrin binds to the integrins ICAM-1, VE-cadherin, αIIbβ3, αMβ2, αvβ3 and α5β1. Fibrin is used in research related to chronic wounds .

HY-18668

Integrin antagonist 27	Integrin	Cancer
Integrin antagonist 27 (Compound 27) is a small molecule integrin αvβ3 antagonist with an affinity of 18 nM. Integrin antagonist 27 can be combined with Paclitaxel (HY-B0015) to selectively target αvβ3-positive metastatic cancer cells. Integrin antagonist 27 is used as an anticancer agent .

HY-P6351

c(avb6)-DOTA TFA	Integrin	Cancer
c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC₅₀=0.8 nM) and can be used as a tumor diagnostic .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-W008201

tert-Butyl 3-formylpyrrolidine-1-carboxylate	Drug Intermediate	Inflammation/Immunology
tert-Butyl 3-formylpyrrolidine-1-carboxylate is a drug intermediate that can be used for the synthesis nonpeptidic αvβ6 Integrin inhibitors .

HY-P1187

HSDVHK-NH2	Integrin	Cancer
HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC₅₀ of 1.74 pg/mL (2.414 pM) .

HY-P5021

Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE) is a cyclic RGD peptide targeting integrin αvβ3. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is commonly used for modifying drug loaded nanoparticles. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is often used in cancer research, such as pancreatic cancer .

HY-P2300A

Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA 2 Publications Verification Cyclo(RGDfC) TFA	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .

HY-P11339

c-RGD-SH	Integrin	Cancer
c-RGD-SH is a ligand for integrin αvβ3 (Integrin αvβ3). Conjugation of c-RGD-SH with core-crosslinked polymeric micelles (CCPM) enables the synthesis of a bimodal nanoprobe, which can be labeled with Cy7 and 111In for SPECT and NIRF imaging of tumors .

HY-19306

SB-267268	Integrin	Cancer
SB-267268 is a selective and nonpeptidic alpha(v)beta3 (αvβ3) and alpha(v)beta5 (αvβ5) integrins antagonist, with K_is of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively. SB-267268 inhibits human and mouse αvβ3 with IC₅₀s of 0.68 and 0.29 nM, respectively. SB-267268 reduces angiogenesis and VEGF expression .

HY-D2062

ATTO 740 NHS ester	Fluorescent Dye Integrin	Cancer
ATTO 740 NHS ester is a near-infrared fluorescent dye and a multimodal fluorescence/photoacoustic contrast agent with excellent near-infrared emission properties and extremely high photostability. The photoacoustic signal of ATTO 740 NHS ester shows no significant decrease after continuous irradiation with a 750 nm laser for 30 min, making it suitable for in vivo fluorescence imaging and photoacoustic contrast imaging. When conjugated with the cystine knot peptide R01, ATTO 740 NHS ester enables precise detection of integrin αvβ6-positive cells and tumors in nude mouse xenograft models .

HY-161730

*αvβ1 integrin-IN-3*	Integrin	Cardiovascular Disease Cancer
αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect .

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-D2439

RGD-PEG-Cy3	Fluorescent Dye	Cancer
RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .

HY-164429

VIP236	Integrin Elastase	Cancer
VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .

HY-153807

*αvβ6 integrin* inhibitor 2**	Integrin	Inflammation/Immunology
αvβ6 integrin inhibitor 2 is a potent ανβ6 integrin inhibitor with an IC₅₀ of 96.5 nM (WO2020081154A1, example 19) .

Cat. No.	Product Name	Type

HY-D2062

ATTO 740 NHS ester

Fluorescent Dyes

ATTO 740 NHS ester is a near-infrared fluorescent dye and a multimodal fluorescence/photoacoustic contrast agent with excellent near-infrared emission properties and extremely high photostability. The photoacoustic signal of ATTO 740 NHS ester shows no significant decrease after continuous irradiation with a 750 nm laser for 30 min, making it suitable for in vivo fluorescence imaging and photoacoustic contrast imaging. When conjugated with the cystine knot peptide R01, ATTO 740 NHS ester enables precise detection of integrin αvβ6-positive cells and tumors in nude mouse xenograft models .

HY-D2439

RGD-PEG-Cy3

Fluorescent Dyes

RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .

Cat. No.	Product Name	Type

HY-172494

DSPE-PEG2000-iRGD	Biochemical Assay Reagents
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an *αv-integrins* targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for agent delivery .

HY-100133A

DOTA-ADIBO TFA	Biochemical Assay Reagents
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-W008201

tert-Butyl 3-formylpyrrolidine-1-carboxylate	Biochemical Assay Reagents
tert-Butyl 3-formylpyrrolidine-1-carboxylate is a drug intermediate that can be used for the synthesis nonpeptidic αvβ6 Integrin inhibitors .

HY-172494A

DSPE-PEG3400-iRGD	Biochemical Assay Reagents
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery .

HY-172495

DSPE-PEG3000-iRGD	Biochemical Assay Reagents
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery .

HY-172493

DSPE-PEG1000-iRGD	Biochemical Assay Reagents
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P0023

Cyclo(-RGDfK) Maximum Cited Publications 27 Publications Verification	Integrin	Cancer
Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC₅₀ of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-100563A

Cyclo(RGDyK) 4 Publications Verification	Integrin	Cancer
Cyclo(RGDyK) is a potent and selective **α_Vβ₃ integrin inhibitor with an IC₅₀** of 20 nM.

HY-P0122

iRGD peptide 5+ Cited Publications c(CRGDKGPDC)	Integrin	Cancer
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to *αv-integrins*, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

HY-P0023A

Cyclo(-RGDfK) TFA Maximum Cited Publications 27 Publications Verification	Integrin	Cancer
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-P2300

Cyclo(Arg-Gly-Asp-D-Phe-Cys) 2 Publications Verification Cyclo(RGDfC)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .

HY-P5133

Synstatin (92-119) 1 Publications Verification SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an inhibitor of αvβ3/αvβ5 integrins and IGF1R with anti-angiogenic, anti-proliferative, antioxidant and anti-tumor activities. Synstatin (92-119) competitively blocks the capture of αvβ3/αvβ5 integrins and IGF1R by syndecan-1, disrupts the formation of the syndecan-1 : integrin : IGF1R ternary complex, inhibits integrin activation and talin-mediated signaling pathways, and blocks VEGF-induced angiogenesis. Synstatin (92-119) is applicable to research related to cancer and hepatocellular carcinoma .

HY-100563

Cyclo(RGDyK) trifluoroacetate 4 Publications Verification	Integrin	Cancer
Cyclo(RGDyK) trifluoroacetate is a potent and selective **α_Vβ₃ integrin inhibitor with an IC₅₀** of 20 nM.

HY-P5098

E(c(RGDfK))2	Integrin	Neurological Disease Cancer
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .

HY-P3732

RGD-4C	Integrin	Cancer
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

HY-P0295

Gly-Arg-Gly-Asp-Ser GRGDS	Integrin	Others
Gly-Arg-Gly-Asp-Ser (GRGDS) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC₅₀ of ～5 and ～6.5 μM

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC₅₀ values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .

HY-P6351

c(avb6)-DOTA TFA	Integrin	Cancer
c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC₅₀=0.8 nM) and can be used as a tumor diagnostic .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P1187

HSDVHK-NH2	Integrin	Cancer
HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC₅₀ of 1.74 pg/mL (2.414 pM) .

HY-P5021

Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE) is a cyclic RGD peptide targeting integrin αvβ3. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is commonly used for modifying drug loaded nanoparticles. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is often used in cancer research, such as pancreatic cancer .

HY-P2300A

Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA 2 Publications Verification Cyclo(RGDfC) TFA	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .

HY-P11339

c-RGD-SH	Integrin	Cancer
c-RGD-SH is a ligand for integrin αvβ3 (Integrin αvβ3). Conjugation of c-RGD-SH with core-crosslinked polymeric micelles (CCPM) enables the synthesis of a bimodal nanoprobe, which can be labeled with Cy7 and 111In for SPECT and NIRF imaging of tumors .

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-175323

NOTA-IMB-RGD	Integrin PD-1/PD-L1	Cancer
NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) .

HY-P2153

Maraciclatide	Integrin	Inflammation/Immunology Cancer
Maraciclatide is a synthetic molecule that binds with high affinity to α_vβ₃ and α_vβ₅ integrins via the RGD peptide. Maraciclatide can be used to detect bone metastasis, breast tumors, vascular disease and rheumatoid arthritis in animal models. Maraciclatide can be studied in research on angiogenesis and inflammation .

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val) Cyclo(RGDfV); C(RGDfV)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .

HY-P11339A

c-RGD-SH TFA	Integrin	Cancer
c-RGD-SH TFA is an Integrin αvβ3 ligand. c-RGD-SH TFA conjugated with core-crosslinked polymeric micelles (CCPM) can be used for synthesis a dual modality nanoparticle probe, and this probe labeled with both Cy7 and ¹¹¹In can be used for SPECT and NIRF imaging of tumor .

HY-P11474

FZ1 peptide	Integrin FAK Akt ERK	Metabolic Disease
FZ1 peptide is an integrin αvβ3 agonist. FZ1 peptide binds to integrin αvβ3, effectively activates FAK, FAK-dependent AKT and ERK1/2 signaling pathways. FZ1 peptide enhances VEGFC-induced endothelial angiogenesis, accelerates diabetic skin wound healing .

HY-P10320

T3 Peptide Tumstatin (69-88), human	PI3K Akt	Cardiovascular Disease
T3 Peptide is an active fragment of tumstatin. T3 Peptide binds integrin α_vβ₃/α_vβ₅, activates the PI3K/Akt/p70S6K signaling pathway, and thus stimulates the proliferation and migration of rat cardiac fibroblasts .

HY-P10704

C16Y	Integrin	Cancer
C16Y is a short peptide and an inhibitor of integrins αvβ3 and α5β1. C16Y acts on the cell membrane and exerts its anticancer activity by inhibiting angiogenesis .

HY-P11424

Cyclo(GRGDSPA)	Integrin	Cancer
Cyclo(GRGDSPA) is a cyclic RGD peptide targeting αvβ3 integrin. Cyclo(GRGDSPA) reduces the formation of colonies in mice injected with B16-FE7 melanoma cells. Cyclo(GRGDSPA) can be used for melanoma research .

HY-P0295A

Gly-Arg-Gly-Asp-Ser TFA GRGDS TFA	Integrin	Inflammation/Immunology
Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin . Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC₅₀ of ∼5 and ∼6.5 μM .

HY-P1187A

HSDVHK-NH2 TFA	Integrin	Cancer
HSDVHK-NH2 TFA is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC₅₀ of 1.74 pg/mL (2.414 pM) .

HY-P10677

HB-3-20	Integrin	Cancer
HB-3-20 leads to degradation of the cell surface integrin α_Vβ₅. Transglutaminase 2 (TG2) has specificity for HB-3-20 (k_cat/K_M=0.16 μM ^-1min ^-1) .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

HY-P11576

Cyclic αvβ6	Integrin Radionuclide-Drug Conjugates (RDCs)	Cancer
Cyclic αvβ6 (Compound c(FRGDLAFp(NMe)K)) is a αvβ6-integrin-specific cyclic nonapeptide. Cyclic αvβ6 can be coupled with ⁶⁸Ga-labeled monomeric triazacyclononane-triphosphinate (TRAP). Cyclic αvβ6 can be used in PET imaging studies for cancers including head and neck cancer and pancreatic cancer .

HY-P11773

3P-RGD2	Radionuclide-Drug Conjugates (RDCs) Integrin	Others
3P-RGD2 is a dimeric cyclic RGD (Arg-Gly-Asp) peptide. When radiolabeled with ^99mTc, 3P-RGD2 serves as a selective radiotracer for integrin α_vβ₃. When radiolabeled with ^99mTc, 3P-RGD2 enables single-photon emission computed tomography imaging of integrin α_vβ₃ .

HY-P11708

Relitegatide	Integrin	Cancer
Relitegatide is a cyclic peptide with selectivity for the αvβ6 integrin. Relitegatide can be used for the synthesis of Relitegatide brexetan (HY-P11276) .

HY-P3335

SU015 DOTA-RGDfK dimer	Integrin Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
SU015 (DOTA-RGDfK dimer) is a *Integrin* α_vβ₅ and α_vβ₃ antagonist. SU015 exhibits comparable affinity for α_vβ₅ and α_vβ₃, with relatively higher potency and specificity compared to other integrins. SU015 inhibits α_vβ₃-mediated cell adhesion to fibrinogen, α_vβ₃-mediated adhesion of activated platelets to osteopontin, and α_vβ₅-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with ⁹⁰Y (i.e., RP697) or ¹⁷⁷Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors .

HY-100563AR

Cyclo(RGDyK) (Standard)	Integrin Reference Standards	Cancer
Cyclo(RGDyK) (Standard) is the analytical standard of Cyclo(RGDyK) (HY-100563A). This product is intended for research and analytical applications. Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.

HY-100563R

Cyclo(RGDyK) trifluoroacetate (Standard)	Integrin Reference Standards	Cancer
Cyclo(RGDyK) (trifluoroacetate) (Standard) is the analytical standard of Cyclo(RGDyK) (trifluoroacetate) (HY-100563). This product is intended for research and analytical applications. Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.

HY-P10704A

C16Y acetate	Integrin	Cancer
C16Y acetate is a short peptide and an inhibitor of integrins αvβ3 and α5β1. C16Y acetate acts on the cell membrane and exerts its anticancer activity by inhibiting angiogenesis .

HY-179583

FSC(PEG4-αvβ6)₃	Integrin	Cancer
FSC(PEG4-avb6)₃ is a tracer targeting αvβ6 integrin trimer (IC₅₀ = 0.69 nM). FSC(PEG4-avb6)₃ can be used for the study of head-and-neck, lung, breast, and pancreatic carcinomas .

HY-P11780

KAFDITYVRLKF	Integrin MMP	Neurological Disease Cancer
KAFDITYVRLKF is a selective, competitive integrin α_vβ₃ binder. KAFDITYVRLKF induces the production of MMP-9. KAFDITYVRLKF blocks monocyte migration, promotes melanoma cell migration, protects neurons, and improves motor and cognitive functions. KAFDITYVRLKF can be used in research related to melanoma and Parkinson's disease .

HY-P11774

HYNIC-3P-RGD2	Integrin	Cancer
HYNIC-3P-RGD2 is a dimeric cyclic RGD peptide with high binding affinity for integrin α_vβ₃ (IC₅₀ = 33 nM). HYNIC-3P-RGD2 acts as a precursor molecule for radiotracers and is used to detect tumor angiogenesis .

HY-P1654A

A20FMDV2-Cys	Integrin	Cancer
A20FMDV2-Cys is a cysteine-containing 20-mer peptide that targets integrin αvβ6 with high affinity. A20FMDV2-Cys can be used for targeted liposome modification to enhance liver and bile duct targeting. A20FMDV2-Cys is applicable for research in drug delivery .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99296

Intetumumab CNTO 95; Anti-Human CD51 Recombinant Antibody	Integrin Apoptosis	Cancer
Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a K_d value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .

HY-P99291

Etaracizumab LM609; MEDI-522	Integrin Apoptosis Akt	Cancer
Etaracizumab (LM 609) is an α_vβ₃ integrin IgG mAb. Etaracizumab is developed to target α_vβ₃+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofα_vβ₃-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990667

STX-100 BG00011	Integrin TGF-beta/Smad	Inflammation/Immunology Cancer
STX-100 (BG00011) is a humanized monoclonal antibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer .

HY-P992085

*Anti-Integrin* αvβ8 Antibody**	Integrin	Inflammation/Immunology
Anti-Integrin αvβ8 Antibody is an anti-human monoclonal antibody targeting integrin αvβ8.

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87744

	Integrin αV Antibody (YA7429)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Integrin αV Antibody (YA7429) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Integrin αV.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-172494

DSPE-PEG2000-iRGD		Pegylated Lipids
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an *αv-integrins* targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for agent delivery .

HY-172494A

DSPE-PEG3400-iRGD		Pegylated Lipids
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery .

HY-172495

DSPE-PEG3000-iRGD		Pegylated Lipids
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery .

HY-172493

DSPE-PEG1000-iRGD		Pegylated Lipids
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

αv integrin

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Antibodies

Oligonucleotides

Natural
Products